NCT03321890
Chidamide Combined With PECM in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
A Multicenter, Single-arm, Open II Phase Clinical Trial Evaluating the Efficacy of Chidamide Combined With Prednisone, Cyclophosphamide, Etoposide, and Methotrexate (PECM) in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Sun Yat-sen University·Phase 2·ClinicalTrials.gov·drug
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- Peripheral T-cell Lymphoma
- Drug/Device/Intervention
- Chidamide
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Sun Yat-sen University
- Location
- Guangzhou, China
Timeline & enrollment
- Phase
- Phase 2
- Start date
- Mar 07, 2017
- End date
- Dec 31, 2020
- Enrollment
- 102 participants
Primary outcome
Objective response rate
Summary
To observe the efficacy and safety of Chidamide combined with prednisone, cyclophosphamide,
 etoposide and methotrexate in relapsed or refractory PTCL.
ICD-10 classifications
Peripheral T-cell lymphoma, not elsewhere classifiedCutaneous T-cell lymphoma, unspecifiedMature T/NK-cell lymphomasAngioimmunoblastic T-cell lymphomaOther mature T/NK-cell lymphomas
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT03321890
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT03321890 through Pure Global AI's free database. This Phase 2 trial is sponsored by Sun Yat-sen University and is currently status unknown. The study focuses on Peripheral T-cell Lymphoma. Target enrollment is 102 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.